XUP Fundamental Analysis - GENFIT

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to XUP. XUP was compared to 81 industry peers in the Biotechnology industry. XUP has a bad profitability rating. Also its financial health evaluation is rather negative. XUP has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

XUP had negative earnings in the past year.

In the past year XUP has reported a negative cash flow from operations.

In multiple years XUP reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: XUP reported negative operating cash flow in multiple years.

1.2 Ratios

XUP's Return On Assets of -17.89% is in line compared to the rest of the industry. XUP outperforms 58.02% of its industry peers.

XUP has a Return On Equity (-73.87%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROIC	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XUP's Profit Margin has declined in the last couple of years.

XUP's Operating Margin has declined in the last couple of years.

XUP has a Gross Margin of 95.42%. This is amongst the best in the industry. XUP outperforms 95.06% of its industry peers.

XUP's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for XUP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.42%

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XUP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, XUP has more shares outstanding

XUP has more shares outstanding than it did 5 years ago.

XUP has a worse debt/assets ratio than last year.

2.2 Solvency

XUP has an Altman-Z score of -1.45. This is a bad value and indicates that XUP is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -1.45, XUP is doing worse than 61.73% of the companies in the same industry.

XUP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.

XUP's Debt to Equity ratio of 0.09 is in line compared to the rest of the industry. XUP outperforms 58.02% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	-1.45

ROIC/WACCN/A

WACC7.08%

2.3 Liquidity

A Current Ratio of 3.74 indicates that XUP has no problem at all paying its short term obligations.

XUP has a Current ratio of 3.74. This is in the better half of the industry: XUP outperforms 67.90% of its industry peers.

A Quick Ratio of 3.74 indicates that XUP has no problem at all paying its short term obligations.

With a decent Quick ratio value of 3.74, XUP is doing good in the industry, outperforming 74.07% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.74
Quick Ratio	3.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for XUP have decreased strongly by -289.19% in the last year.

The earnings per share for XUP have been decreasing by -70.77% on average. This is quite bad

Looking at the last year, XUP shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.

The Revenue has been growing by 11.61% on average over the past years. This is quite good.

EPS 1Y (TTM)-289.19%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-137.74%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-45.28%

3.2 Future

XUP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.44% yearly.

The Revenue is expected to decrease by -1.86% on average over the next years.

EPS Next Y-110.7%

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

EPS Next 5Y-29.44%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-1.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XUP. In the last year negative earnings were reported.

Also next year XUP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

XUP's earnings are expected to decrease with -45.26% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XUP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENFIT

FRA:XUP (11/26/2025, 7:00:00 PM)

3.964

+0.22 (+5.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-20 2025-11-20

Earnings (Next)04-22 2026-04-22/amc

Inst Owners0.76%

Inst Owner ChangeN/A

Ins Owners0.18%

Ins Owner ChangeN/A

Market Cap198.21M

Revenue(TTM)45.41M

Net Income(TTM)-38.76M

Analysts90.77

Price Target9.03 (127.8%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.36
P/FCF	N/A
P/OCF	N/A
P/B	3.78
P/tB	93.23
EV/EBITDA	N/A

EPS(TTM)-0.7

EYN/A

EPS(NY)-0.68

Fwd EYN/A

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)-0.07

OCFYN/A

SpS0.91

BVpS1.05

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.42%
FCFM	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

F-Score2

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.46%
Cap/Sales	7.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.74
Quick Ratio	3.74
Altman-Z	-1.45

F-Score2

WACC7.08%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-289.19%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-137.74%

EPS Next Y-110.7%

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

EPS Next 5Y-29.44%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-45.28%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-1.86%

EBIT growth 1Y-216.85%

EBIT growth 3Y-53.58%

EBIT growth 5YN/A

EBIT Next Year-6.17%

EBIT Next 3Y-0.9%

EBIT Next 5YN/A

FCF growth 1Y87.25%

FCF growth 3Y-47.27%

FCF growth 5YN/A

OCF growth 1Y93.33%

OCF growth 3Y-46.21%

OCF growth 5YN/A

GENFIT / XUP.DE FAQ

What is the fundamental rating for XUP stock?

ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE.

What is the valuation status for XUP stock?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT (XUP.DE). This can be considered as Overvalued.

How profitable is GENFIT (XUP.DE) stock?

GENFIT (XUP.DE) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for XUP stock?

The Earnings per Share (EPS) of GENFIT (XUP.DE) is expected to decline by -110.7% in the next year.

GENFIT (XUP.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GENFIT / XUP.DE FAQ

What is the fundamental rating for XUP stock?

What is the valuation status for XUP stock?

How profitable is GENFIT (XUP.DE) stock?

Can you provide the expected EPS growth for XUP stock?